- XL019
-
- $68.00 / 5mg
-
2024-11-17
- CAS:945755-56-6
- Min. Order:
- Purity: 99.23%
- Supply Ability: 10g
- XL019
-
- $2.00 / 1kg
-
2019-07-06
- CAS:945755-56-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| Product Name: | XL019 | | Synonyms: | 2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide XL019;XL019 2-Pyrrolidinecarboxamide, N-[4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-, (2S)-;Pyrrolidine-2-carboxylic acid {4-[2-(4-morpholin-4-yl-phenylamino)-pyrimidin-4-yl]-phenyl}-amide;XL019, >=98%;XL019;XL019/XL-019;(2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide;(S)-N-(4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)PHENYL)PYRROLIDINE-2-CARBOXAMIDE | | CAS: | 945755-56-6 | | MF: | C25H28N6O2 | | MW: | 444.53 | | EINECS: | | | Product Categories: | JAK;Inhibitors;STAT | | Mol File: | 945755-56-6.mol |  |
| | XL019 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | insoluble in EtOH; insoluble in H2O; ≥11.125 mg/mL in DMSO | | form | solid | | color | Green to yellow |
| | XL019 Usage And Synthesis |
| Uses | XL019 is used in the synthesis of JAK-2 modulators for the treatment of related diseases. | | Biological Activity | XL019 is an ATP-binding site-targeting, orally active JAK2 subtype-selective Janus kinase inhibitor (IC50 in nM = 2.2/JAK2 vs. 134.3/JAK1, 214.2/JAK3, 348.3/TYK2) with much reduced or little activity against 116 other kinases (IC50 in nM = 125.4/PDGFRB, 139.7/FLT3, 225.8/c-KIT, 313.8/p70S6K, 370/MLK1, 375.4/IKKbeta, 483.6/KDR, 546.7/PDGFRA, 554.5/FLT4, 910.5/FLT; IC50 >1 μM toward remaining 106 kinases), CYP (1A2, 2C9, 2D6, 3A4 IC50 ≥20 μM), hERG (IC50 = 16 μM), and P-glycoprotein (IC50 >20 μM). XL019 effectively inhibits cellular STAT1/STAT3 phosphorylation both in HEL92.1.7 cultures (IC50 in nM = 386.4/pStat1 and 695/pStat3) and in HEL92.1.7 xenograft-derived tumor in mice in vivo (oral ED50 in mg/kg = 42/pStat1 and 210/pStat3) with significant HEL92.1.7 tumor suppression efficacy in mice (by 60% and 70% on day 14, respectively, with 200 and 300 mg/kg bid p.o. dosage). | | target | JAK2 |
| | XL019 Preparation Products And Raw materials |
|